Dr. Rudolf Lucas is committed to highest standard of excellence at pulmonology department , apeptico in austria. He has worked for more than 10 years in the related field and gained a plethora of knowledge in related field. His international experience includes various programs, contributions to reputed journals and participation in different international conferences in diverse fields of study.
research activities focus on the identification of novel therapeutic candidates blunting pulmonary barrier dysfunction induced by bacterial and viral compounds. The recently discovered TNF-derived TIP peptide is currently in clinical trials as a candidate drug for treating pulmonary permeability edema. Moreover, in collaboration with Nobel laureate Dr Andrew V. Schally, Univ. Miami, Dr. Chakraborty, JLU, Germany and Dr Matthay, UCSF, we are evaluating GHRH agonists in pneumonia models